There are some details in the AMA that Parrish hosted, but not the specific technique or vector used. One can probably make educated guesses based on who was involved and their past work. It was a whole-body approach, not targeted to any specific tissue. Telomere length was measured in white blood cells because that is the present standard assay in the scientific community, not because immune cells were targeted specifically:<p><a href="https:&#x2F;&#x2F;www.reddit.com&#x2F;r&#x2F;Futurology&#x2F;comments&#x2F;3ocsbi&#x2F;ama_my_name_is_liz_parrish_ceo_of_bioviva_the&#x2F;" rel="nofollow">https:&#x2F;&#x2F;www.reddit.com&#x2F;r&#x2F;Futurology&#x2F;comments&#x2F;3ocsbi&#x2F;ama_my_n...</a><p>&quot;The genes targeted are human telomerase reverse transcriptase (hTERT) and follistatin (FST). In animal models neither FST nor hTERT have increased the risk of cancer. We expect to see the same result on myself, and to that effect we are measuring all known cancer biomarkers. The gene therapies on my body are to measure the effects on humans. There is plenty of animal research to support these gene therapies but no one was conducting human tests. We are using both visual biomarkers, MRI and a panel of blood and tissue testing including work on telomere length and epigenetic testing. We are collecting as much data as we can, but unfortunately we currently don&#x27;t have the coverage rate for this therapy, how much of the tissue of the body is affected. Depending on the tissue and vector used we ultimately expect to see similar rates of transfection as seen in mice, which is somewhere between 5 to 60%.&quot;